---
title: "RIBBON ACQUISITION CORP COM USD0.0001 CL A 31/12/2026(SUB/RIGHT) | 10-Q: FY2025 Q2 EPS: USD 0.11"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252913346.md"
datetime: "2025-08-13T20:09:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252913346.md)
  - [en](https://longbridge.com/en/news/252913346.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252913346.md)
generator: "portal-rs"
---

# RIBBON ACQUISITION CORP COM USD0.0001 CL A 31/12/2026(SUB/RIGHT) | 10-Q: FY2025 Q2 EPS: USD 0.11

EPS: As of FY2025 Q2, the actual value is USD 0.11.

### Segment Revenue

-   No revenue reported as the company has not commenced operations and is focused on completing its initial business combination.

### Operational Metrics

-   **Net Income**: For the three months ended June 30, 2025, net income was $271,297. For the six months ended June 30, 2025, net income was $507,153.
-   **Operating Expenses**: For the three months ended June 30, 2025, operating expenses were $242,894. For the six months ended June 30, 2025, operating expenses were $428,295.
-   **Income Earned on Marketable Securities**: For the three months ended June 30, 2025, income earned on marketable securities held in the Trust Account was $514,191. For the six months ended June 30, 2025, income earned on marketable securities held in the Trust Account was $935,448.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was - $418,288.
-   **Net Cash Used in Investing Activities**: For the six months ended June 30, 2025, net cash used in investing activities was - $50,000,000.
-   **Net Cash Provided by Financing Activities**: For the six months ended June 30, 2025, net cash provided by financing activities was $50,710,916.
-   **Cash at End of Period**: As of June 30, 2025, cash at the end of the period was $292,628.

### Unique Metrics

-   **Accretion of Ordinary Shares Subject to Redemption Value**: For the six months ended June 30, 2025, the company recorded accretion of ordinary shares subject to redemption value of $2,800,290.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is focused on completing its initial business combination within the prescribed timeline, which is by January 16, 2026. The company has entered into a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd., and DRC Merger Inc., with the goal of merging and creating a new entity, PubCo.
-   **Non-Core Business**: The company has no current operations and is solely focused on completing the business combination. There are no plans related to divestitures or emerging segments mentioned.
-   **Priority**: The primary strategy is to complete the business combination with DRC Medicine and ensure the successful transition and integration of the new entity, PubCo.

### Related Stocks

- [RIBBR.US](https://longbridge.com/en/quote/RIBBR.US.md)

## Related News & Research

- [Gas supply cut from Indonesia accounts for less than 2% of Singaporeâs daily gas demand: EMA](https://longbridge.com/en/news/302973681.md)
- [Results: Billerud AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates](https://longbridge.com/en/news/302983070.md)
- [Kuehne + Nagel International AG - Depositary receipt consensus price target raised 13.43% to $52.60](https://longbridge.com/en/news/302982717.md)
- [Dongshan Precision retail IPO undersubscribed as Hong Kong mega listing flops](https://longbridge.com/en/news/302974270.md)
- [Crypto Strategist Who Nailed 2025 Bitcoin Top Warns BTC Could Drop Below $70,000 – Here’s His Price Target](https://longbridge.com/en/news/302980144.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**